A nanoparticle-based tour de force for enhancing immunogenic cell death elicited by photodynamic therapy.
Journal
Oncoimmunology
ISSN: 2162-402X
Titre abrégé: Oncoimmunology
Pays: United States
ID NLM: 101570526
Informations de publication
Date de publication:
2022
2022
Historique:
entrez:
14
7
2022
pubmed:
15
7
2022
medline:
16
7
2022
Statut:
epublish
Résumé
Immunogenic cell death (ICD) involves the release of ATP, which can be destroyed by ectonucleotidases, converting it into immunosuppressive adenosine. Hence, inhibition of such ectonucleotidases is a strategy for enhancing ICD-elicited anticancer immunity. In a recent paper in Science Translational Medicine, Mao et al. report the construction of reactive oxygen-labile nanoparticles that bear two functionalities, namely (i) the capacity to sensitize cancer cells to near-infrared light (NIL) irradiation, hence inducing ICD in the context of photodynamic therapy, and (ii) the peculiarity to respond to NIL by releasing a pharmacological inhibitor of ectonucleotidases, hence enhancing intratumoral concentrations of ATP. In preclinical models, these nanoparticles are highly efficient in inducing anticancer immune responses.
Identifiants
pubmed: 35832042
doi: 10.1080/2162402X.2022.2098658
pii: 2098658
pmc: PMC9272828
doi:
Substances chimiques
Adenosine Triphosphate
8L70Q75FXE
Types de publication
Editorial
Research Support, Non-U.S. Gov't
Comment
Langues
eng
Sous-ensembles de citation
IM
Pagination
2098658Commentaires et corrections
Type : CommentOn
Informations de copyright
© 2022 Taylor & Francis Group, LLC.
Références
Nat Rev Immunol. 2017 Apr;17(4):262-275
pubmed: 28287107
Nat Rev Clin Oncol. 2020 Jan;17(1):49-64
pubmed: 31595049
Nat Rev Clin Oncol. 2020 Oct;17(10):611-629
pubmed: 32514148
Nat Immunol. 2022 Apr;23(4):487-500
pubmed: 35145297
Nat Rev Immunol. 2020 Dec;20(12):739-755
pubmed: 32728220
Sci Transl Med. 2022 Jun 8;14(648):eabh1261
pubmed: 35675434
Oncoimmunology. 2020 Feb 11;9(1):1721810
pubmed: 32117585
Oncoimmunology. 2021 Nov 2;10(1):1996686
pubmed: 34745770
EMBO J. 2021 Jul 1;40(13):e108130
pubmed: 34121201
Nat Cancer. 2020 Sep;1(9):860-861
pubmed: 35121951